001     266790
005     20240808170924.0
024 7 _ |a 10.1007/s00415-023-11985-8
|2 doi
024 7 _ |a pmid:37737892
|2 pmid
024 7 _ |a pmc:PMC10769984
|2 pmc
024 7 _ |a 0367-004X
|2 ISSN
024 7 _ |a 0012-1037
|2 ISSN
024 7 _ |a 0340-5354
|2 ISSN
024 7 _ |a 1432-1459
|2 ISSN
024 7 _ |a altmetric:154529363
|2 altmetric
037 _ _ |a DZNE-2024-00048
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wiesenfarth, Maximilian
|0 0009-0004-0187-5973
|b 0
245 _ _ |a Neurological manifestation of HEV infection: still a rare disease entity?
260 _ _ |a Heidelberg
|c 2024
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1705503606_18422
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Hepatitis E virus (HEV) infection is the most common form of viral hepatitis and is reported to cause neurological manifestation in up to 30% of diagnosed infections. We evaluated the medical reports of all patients (n = 29,994) who were discharged from the Department of Neurology of Ulm University between 01.01.2015 and 30.09.2022 to detect neurological manifestations of HEV. In addition, we retrospectively analyzed the serum samples of n = 99 patients representing different neurological diseases possibly related to HEV for anti-HEV-IgM and anti-HEV-IgG. At the time of discharge from hospital, the etiology of neurological symptoms in these patients was unclear. Overall, five cases of extrahepatic neurological manifestation of HEV (defined as anti-HEV-IgM and HEV-IgG positive) could be detected. An increase of both, anti-IgM- and anti-IgG-serum levels was significantly more common in neuralgic amyotrophy/plexus neuritis/radiculitis than in AIDP/CIDP (P = 0.01), meningitis/encephalitis (P = 0.02), idiopathic peripheral facial paralysis (P = 0.02) and tension headache (P = 0.02). In 15% (n = 15 out of 99) of retrospectively analyzed serum samples, conspicuous positive anti-HEV-IgG levels were detected. This finding was most common in AIDP/CIDP. In conclusion, results of this study indicate neurological manifestation of HEV to be a rare but still underestimated course of disease, occurring at any age and gender. Therefore, testing for HEV should be considered in patients with neurological symptoms of unknown origin, especially in those with neuralgic amyotrophy/plexus neuritis.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Hepatitis E virus
|2 MeSH
650 _ 2 |a Brachial Plexus Neuritis: diagnosis
|2 MeSH
650 _ 2 |a Brachial Plexus Neuritis: etiology
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: complications
|2 MeSH
650 _ 2 |a Rare Diseases: complications
|2 MeSH
650 _ 2 |a Hepatitis E: complications
|2 MeSH
650 _ 2 |a Hepatitis E: diagnosis
|2 MeSH
650 _ 2 |a Hepatitis Antibodies
|2 MeSH
650 _ 2 |a Immunoglobulin M
|2 MeSH
650 _ 2 |a Immunoglobulin G
|2 MeSH
650 _ 7 |a Guillain–Barré syndrome
|2 Other
650 _ 7 |a Guillain–Barré syndrome
|2 Other
650 _ 7 |a Guillain–Barré syndrome
|2 Other
650 _ 7 |a Encephalitis
|2 Other
650 _ 7 |a Guillain–Barré syndrome
|2 Other
650 _ 7 |a Hepatitis E virus
|2 Other
650 _ 7 |a Neuralgic amyotrophy
|2 Other
650 _ 7 |a Neurological manifestation
|2 Other
650 _ 7 |a Plexus neuritis
|2 Other
650 _ 7 |a Hepatitis Antibodies
|2 NLM Chemicals
650 _ 7 |a Immunoglobulin M
|2 NLM Chemicals
650 _ 7 |a Immunoglobulin G
|2 NLM Chemicals
700 1 _ |a Stamminger, Thomas
|b 1
700 1 _ |a Zizer, Eugen
|b 2
700 1 _ |a Tumani, Hayrettin
|0 P:(DE-2719)9002007
|b 3
|u dzne
700 1 _ |a Ludolph, Albert C
|0 P:(DE-2719)2812633
|b 4
|e Last author
|u dzne
773 _ _ |a 10.1007/s00415-023-11985-8
|g Vol. 271, no. 1, p. 386 - 394
|0 PERI:(DE-600)1421299-7
|n 1
|p 386 - 394
|t Journal of neurology
|v 271
|y 2024
|x 0367-004X
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/266790/files/DZNE-2024-00048.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/266790/files/DZNE-2024-00048.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:266790
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9002007
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812633
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NEUROL : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center Ulm
|l Clinical Study Center Ulm
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000077
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21